Serina Therapeutics (NYSEAMERICAN:SER) Stock Keeps Buy Rating at BTIG Research

Serina Therapeutics (NYSEAMERICAN:SER)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research‘s target price suggests a potential upside of 377.61% from the company’s current price.

Serina Therapeutics Price Performance

SER traded up $0.03 during midday trading on Monday, hitting $1.68. The stock had a trading volume of 36,192 shares, compared to its average volume of 1,431,764. The company has a market cap of $42.55 million, a P/E ratio of -0.89 and a beta of 1.19. The business has a fifty day moving average of $2.24 and a 200 day moving average of $2.08. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. Serina Therapeutics has a 1 year low of $1.22 and a 1 year high of $5.25.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its earnings results on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.

About Serina Therapeutics

Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability.

Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.